Overview

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Status:
Recruiting

Trial end date:
2029-07-31

Target enrollment:

Participant gender:

Summary

To find out if adding pembrolizumab to standard of care chemotherapy drugs (cisplatin and gemcitabine) will improve long-term response of intrahepatic cholangiocarcinoma after surgery, compared to treatment with surgery and standard chemotherapy alone.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Gemcitabine
Pembrolizumab